Filter News
Area of Research
- (-) Nuclear Science and Technology (4)
- (-) Quantum information Science (1)
- Advanced Manufacturing (2)
- Biological Systems (1)
- Biology and Environment (40)
- Clean Energy (70)
- Climate and Environmental Systems (1)
- Computational Biology (1)
- Computational Engineering (1)
- Computer Science (3)
- Fusion and Fission (4)
- Isotopes (4)
- Materials (39)
- Materials for Computing (5)
- National Security (29)
- Neutron Science (21)
- Supercomputing (74)
News Topics
- (-) Biomedical (1)
- (-) Cybersecurity (1)
- (-) Transformational Challenge Reactor (3)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (6)
- Bioenergy (2)
- Computer Science (4)
- Coronavirus (1)
- Decarbonization (1)
- Fusion (7)
- Isotopes (4)
- Materials Science (3)
- Microscopy (2)
- Molten Salt (1)
- Nanotechnology (1)
- Neutron Science (2)
- Nuclear Energy (23)
- Physics (2)
- Quantum Science (5)
- Space Exploration (3)
- Sustainable Energy (2)
Media Contacts
It’s a new type of nuclear reactor core. And the materials that will make it up are novel — products of Oak Ridge National Laboratory’s advanced materials and manufacturing technologies.
Scientists at the Department of Energy Manufacturing Demonstration Facility at ORNL have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023.
Researchers at the Department of Energy’s Oak Ridge National Laboratory are refining their design of a 3D-printed nuclear reactor core, scaling up the additive manufacturing process necessary to build it, and developing methods
Three researchers at Oak Ridge National Laboratory will lead or participate in collaborative research projects aimed at harnessing the power of quantum mechanics to advance a range of technologies including computing, fiber optics and network
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.